The U.S. Food and Drug Administration today approved Xiaflex (collagenase clostridium histolyticum) as the first drug to treat a progressive hand disease known as Dupuytren's contracture, which can affect a person’s ability to straighten and properly use their fingers.
Xiaflex is manufactured by Auxilium Pharmaceuticals Inc., a specialty
biopharmaceutical company based in Malvern, Penn.
To read the full FDA press release, click here.
has anyone had any experience with billing for the Xiaflex? are CPT's 20550-51 and J3490 the correct codes? has anyone gotten any reimbursement for Xiaflex?ReplyDelete